Table 1.
Characteristic | % of sample (n) |
---|---|
Sex | |
Female | 37% (126) |
Male | 63% (213) |
Race | |
White | 60% (204) |
Black | 37% (127) |
Other | 2% (8) |
Age, mean (SD) | 57.0 (10.1) |
≤49 years old | 21% (71) |
50–59 | 41% (140) |
60–69 | 27% (92) |
70+ | 11% (36) |
Employment status | |
Employed | 12% (41) |
Unemployed | 61% (208) |
Retired | 27% (90) |
Number of visits, total n | 636 |
Mean (SD) | 1.9 (1.8) |
1 visit | 63% (212) |
2 visits | 18% (62) |
3 visits | 8% (28) |
4 visits | 5%(16) |
5+ visits | 6% (21) |
Ever transplanteda | 1% (5/339) |
Pharmaceutical use at admission | |
Proton pump inhibitors | 40% (136/339) |
Beta blockers | 40% (137/339) |
Rifaxamin | 14% (46/339) |
AKI | 29% (96/330) |
AKIN stage | |
No AKI | 71% (234) |
1a | 18% (60) |
1b | 7% (23) |
2 | 2% (7) |
3 | 2% (2) |
Survival | |
In-hospital | 94% (317/339) |
30 days | 85% (286/338) |
90 days | 77% (255/331) |
180 days | 70% (222/319) |
365 days | 59% (172/293) |
Discharge status listed as “Transfer”.